As reported by Sato et al., IL-6 is upregulated in the saliva during the treatment of patients with OSCC relative to the level in control subjects [63], and a higher T-stage and clinical stage, deeper bone invasion and larger tumor depth, as well as a lower OSCC patient survival, are correlated with higher IL-6 levels [64]. Here, IL6 is linked to neoplasm.